Glaxo’s patent for Zantac’s active ingredient, ranitidine, expired in 1997. That same year, pharmaceutical companies began ...

Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

The four being recalled are Zantac 150mg/10ml Syrup ... to quarantine all products which may contain the active pharmaceutical ingredient (API) that is potentially affected by this issue.

as well as GSK — to pull Zantac off the market over mounting concerns that its active ingredient, ranitidine, could degrade into an organic chemical called NDMA, over time or when exposed to heat.

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

US regulatory authorities made the decision to withdraw Zantac from the market due to concerns that its active ingredient, ranitidine, could convert into a potentially cancer-causing substance ...

Settling the cases is not an admission of liability, the company said. Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA ...